SEC Form 4 · accession 0001437749-19-002787
BIOLIFE SOLUTIONS INC · BLFS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Rice
Officer — President & CEO · Director
Period of report
Feb 13, 2019
Accepted (ET)
Feb 15, 2019 · 9:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000834365
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 13, 2019 | M | 7,088 | $1.40 | A | 146,605 | D | |
| Common StockF2 | Feb 13, 2019 | S | 7,088 | $16.03 | D | 139,517 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock OptionF3 | $1.40 | Feb 13, 2019 | M | 7,088 | D | — | Feb 4, 2020 | Common Stock | 7,088 | 77,974 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2018.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.94 to $16.35, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3Option vested equally over four years commencing on February 5, 2011.